The Promega Canine PD-1/PD-L1 Blockade bioassay is enabling a new generation of immune checkpoint antibody research and accelerating therapeutic development for canine cancer while, at the same time, yielding new knowledge of pathways relevant to human oncology. The post Advancing Canine Cancer Immunotherapy through One Health Comparative Oncology Research appeared first on Promega Connections .